RARE
NASDAQ · Biotechnology
Ultragenyx Pharmaceutical In
$15.62
-1.54 (-8.97%)
Performance
1D
—
1W
-2.98%
1M
+4.90%
3M
-41.72%
6M
-40.61%
1Y
-49.53%
YTD
-33.81%
Open$17.07
Previous Close$17.16
Day High$17.13
Day Low$15.49
52W High$39.89
52W Low$12.73
Volume—
Avg Volume2.95M
Market Cap1.65B
P/E Ratio—
EPS$-5.84
SectorBiotechnology
Technical Indicators
Full analysis →
SMA 50
$16.45
Below
SMA 200
$22.80
Below
RSI (14)
65.9
Neutral
Trend
Death Cross
Bearish
Analyst Ratings
Buy
26 analysts
Price Target
+376.6% upside
Current
$15.62
$15.62
Target
$74.44
$74.44
$68.49
$74.44 avg
$103.74
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 656.50M | 534.56M | 933.24M |
| Net Income | -560,891,899 | -411,043,652 | 54.30M |
| Profit Margin | -85.4% | -81.2% | 5.8% |
| EBITDA | -514,070,756 | -397,660,791 | 81.20M |
| Free Cash Flow | — | — | 84.57M |
| Rev Growth | +22.8% | +22.8% | -2.9% |
| Debt/Equity | 3.41 | 3.41 | 0.13 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $288.24 | -2.24% | 81.4 | 513.86B |
| AMGN | Amgen Inc | $460.28 | -3.80% | 28.5 | 249.09B |
| GILD | Gilead Sciences Inc | $167.57 | -3.96% | — | 212.04B |
| VRTX | Vertex Pharmaceuticals Inc | $542.50 | -1.19% | 30.6 | 134.77B |
| REGN | Regeneron Pharmaceuticals | $902.90 | -2.98% | 19.5 | 84.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.66 | -2.74% | 28.8 | 23.28B |